The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties. GSK to purchase $9 million in shares of Spero common stock LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license… Source link
Read More »Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) informed the Company in a teleconference on August 20, 2021, that its review of the new drug application (NDA) for AXS-05 for the treatment of major depressive disorder would not be completed by the Prescription Drug User Fee… Source link
Read More »Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform
Financing led by Casdin Capital, Sofinnova Partners – initial seed investor, and an undisclosed investor Mnemo delivers epigenetic antigens, stronger T cells and best-in-class manufacturing established with groundbreaking research from Institut Curie and Memorial Sloan Kettering PARIS, June 16, 2021 /PRNewswire/ — Mnemo Therapeutics, a biotechnology company developing powerful cell therapies using a novel target identification engine, stronger T cells and best-in-class manufacturing, today… Source link
Read More »Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 17,500,000 of its ordinary… Source link
Read More »